DiaMedica Therapeutics Inc.
DMACDiaMedica reported a net loss of $32.8M in FY2025, a 34% increase from the prior year, driven by expanded clinical development activities, with free cash flow usage rising to $29.1M.
NASDAQ
Healthcare
Biotechnology
$6.47
+0.05(0.78%)
52W $3.38 – $9.39
AI-generated
DiaMedica reported a net loss of $32.8M in FY2025, a 34% increase from the prior year, driven by expanded clinical development activities, with free cash flow usage rising to $29.1M.
$337MMkt Cap
—Rev TTM
-$34MNI TTM
-11.3xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 29, 2026DiaMedica reported a net loss of $32.8M in FY2025, a 34% increase from the prior year, driven by expanded clinical development activities, with free cash flow usage rising to $29.1M.
Fundamentals
How The Business Makes Money
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Industry Biotechnology
Analyst View
Company Profile
CIK0001401040
ISINCA25253X2077
CUSIP25253X207
Phone763 612 6755
AddressTwo Carlson Parkway, Minneapolis, MN, 55447, US
SEC EDGAR